Wire · opportunities
Biotech Begins Gene Therapy Trial for Vision Loss
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 November 2026 · Fusion42 review
Life Biosciences has started dosing patients in a Phase 1 trial for ER-100, an experimental gene therapy targeting vision loss from glaucoma and optic nerve disease, conditions with no current approved treatments. Early clinical results are expected in late 2026, with primary trial completion in May 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You must track early trial data from Life Biosciences; vision treatment options are poised to change where none existed. Prepare to position your biotech to engage if early results validate this gene therapy approach.
◆ Coverage
1 source · 22 Nov 2026
◆ Related on Wire
◆ Topics